SAN MATEO, Calif., Sept. 8, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a company focused on the development of novel therapeutics for cardiovascular disease, today announced that Daron Evans, Chief Financial Officer, will present at the Rodman & Renshaw 13th Annual Global Investment Conference on Tuesday, September 13, 2010 at 2:50 p.m. (Eastern Time) at The Waldorf Astoria in New York City, New York..
About Nile Therapeutics
Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, cenderitide, a novel rationally-designed chimeric peptide in clinical studies for the treatment of heart failure. More information on Nile can be found at http://www.nilethera.com.
SOURCE Nile Therapeutics, Inc.
